Akebia Therapeutics Soars 15.85% on Earnings Surprise

Akebia Therapeutics' stock surged 15.85% in pre-market trading on May 8, 2025, driven by strong first-quarter earnings and revenue surprises.

Akebia Therapeutics reported a 200% earnings surprise and a 26.83% revenue surprise for the quarter ended March 2025. The company's performance exceeded analyst expectations, contributing to the significant pre-market rally.

The consensus earnings per share (EPS) estimate for the first quarter of 2025 was -$0.04, while the consensus revenue estimate was $44.53 million, representing a 36.6% year-over-year increase. Akebia Therapeutics has a history of beating EPS estimates, which further bolstered investor confidence.

Looking ahead, the company's fiscal year 2025 and 2026 estimate trends show a mix of positive and negative projections, indicating a range of expectations among analysts. However, the strong Q1 performance suggests that Akebia Therapeutics is on track to meet or exceed these estimates.